SCHEMBL15480561

SCHEMBL15480561

O=C(NO)c1ccc(NS(=O)(=O)c2ccc(C(=O)N3CCOCC3)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.60
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ ALDH1A1 P00352 3/20 0.57
▸ HDAC3 O15379 2/20 0.56
▸ HDAC11 Q96DB2 2/20 0.56
▸ HDAC8 Q9BY41 2/20 0.56
▸ HDAC6 Q9UBN7 2/20 0.56
▸ MAPK1 P28482 2/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ LMNA P02545 3/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480560 0.88 NPC1 (0.75) POLBNPC1RAB9AALDH1A1HDAC3
SCHEMBL10093052 0.84 POLB (0.62) POLBNPC1RAB9AALDH1A1MAPK1
SCHEMBL15480624 0.78 MAPT (0.56) POLBRAB9AALDH1A1MAPK1L3MBTL1
SCHEMBL15482013 0.76 HDAC8 (0.71) POLBALDH1A1HDAC3HDAC11HDAC8
SCHEMBL15480558 0.74 HDAC8 (0.74) ALDH1A1HDAC3HDAC11HDAC8HDAC6
SCHEMBL15480542 0.74 HDAC3 (0.69) POLBALDH1A1HDAC3HDAC11HDAC8
SCHEMBL15480539 0.74 HDAC3 (0.74) POLBALDH1A1HDAC3HDAC11HDAC8
SCHEMBL15480530 0.74 HDAC6 (0.74) ALDH1A1HDAC3HDAC11HDAC8HDAC6
SCHEMBL15480573 0.74 MEN1 (0.53) POLBNPC1RAB9AALDH1A1HDAC8
SCHEMBL15480538 0.74 MEN1 (0.71) ALDH1A1HDAC3HDAC11HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 — — US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 POLB 2496/4885NPC1 2251/4885RAB9A 3597/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 POLB 2496/4885NPC1 2251/4885RAB9A 3597/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 POLB 2496/4885NPC1 2251/4885RAB9A 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback